Warding Off Recurrent Yeast and Bacterial Vaginal Infections: Lactoferrin and Lactobacilli

Fabiana Superti, Francesco De Seta, Fabiana Superti, Francesco De Seta

Abstract

Vaginal infections are the most prevalent women's health problem. Incompetent diagnosis, inappropriate treatments, and antibiotic resistance are the main causes of the unsatisfactory results of conventional, antimicrobic treatment for these infections. Research has thus been conducted to identify new treatments for these genital diseases. The significant enhancement in our knowledge of vaginal microbiota has permitted the development of new, nonpharmacological strategies for the treatment of vaginal infections that seek to restore the balance of vaginal microflora, as opposed to modifying its components. Among these approaches, bioactive compounds, such as probiotics and nutraceutical proteins (such as lactoferrin), deserve particular attention. The aim of this review is to examine the role of probiotics (mainly Lactobacillus spp.) and lactoferrin as new strategies for counteracting bacterial and fungal vaginal infections.

Keywords: Lactobacillus; aerobic vaginitis; bacterial vaginosis; lactoferrin; safety; vulvovaginal candidiasis.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ma B., Forney L.J., Ravel J. Vaginal microbiome: Rethinking health and disease. Annu. Rev. Microbiol. 2012;66:371–389. doi: 10.1146/annurev-micro-092611-150157.
    1. Ravel J., Gajer P., Abdo Z., Schneider G.M., Koenig S.S., McCulle S.L., Karlebach S., Gorle R., Russell J., Tacket C.O., et al. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. USA. 2011;108:4680–4687. doi: 10.1073/pnas.1002611107.
    1. Zhou X., Brown C.J., Abdo Z., Davis C.C., Hansmann M.A., Joyce P., Foster J.A., Forney L.J. Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women. ISME J. 2007;1:121–133. doi: 10.1038/ismej.2007.12.
    1. Mastromarino P., Vitali B., Mosca L. Bacterial vaginosis: A review on clinical trials with probiotics. New Microbiol. 2013;36:229–238.
    1. Mulu W., Yimer M., Zenebe Y., Abera B. Common causes of vaginal infections and antibiotic susceptibility of aerobic bacterial isolates in women of reproductive age attending at Felegehiwot Referral Hospital, Ethiopia: A cross sectional study. BMC Womens Health. 2015;15:42. doi: 10.1186/s12905-015-0197-y.
    1. Donders G.G., Van Calsteren K., Bellen G., Reybrouck R., Van den Bosch T., Riphagen I., Van Lierde S. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG. 2009;116:1315–1324. doi: 10.1111/j.1471-0528.2009.02237.x.
    1. Jahic M., Mulavdic M., Nurkic J., Jahic E., Nurkic M. Clinical characteristics of aerobic vaginitis and its association to vaginal candidiasis, trichomonas vaginitis and bacterial vaginosis. Med. Arch. 2013;67:428–430. doi: 10.5455/medarh.2013.67.428-430.
    1. Turovskiy Y., Noll K.S., Chikindas M.L. The etiology of bacterial vaginosis. J. Appl. Microbiol. 2011;110:1105–1128. doi: 10.1111/j.1365-2672.2011.04977.x.
    1. Rampersaud R., Randis T.M., Ratner A.J. Microbiota of the upper and lower genital tract. Semin. Fetal Neonatal Med. 2012;17:51–57. doi: 10.1016/j.siny.2011.08.006.
    1. Zarbo G., Coco L., Leanza V., Genovese F., Leanza G., D’Agati A., Giannone T.T., Giunta M.R., Palumbo M.A., Carbonaro A., et al. Aerobic vaginitis during pregnancy. Res. Obstet. Gynecol. 2013;2:7–11. doi: 10.5923/j.rog.20130202.01.
    1. Srinivasan U., Misra D., Marazita M.L., Foxman B. Vaginal and oral microbes, host genotype and preterm birth. Med. Hypotheses. 2009;73:963–975. doi: 10.1016/j.mehy.2009.06.017.
    1. Donders G.G. Definition and classification of abnormal vaginal flora. Best Pract. Res. Clin. Obstet. Gynaecol. 2007;21:355–373. doi: 10.1016/j.bpobgyn.2007.01.002.
    1. Donders G.G., Vereecken A., Bosmans E., Dekeersmaecker A., Salembier G., Spitz B. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: Aerobic vaginitis. BJOG Int. J. Obstet. Gynaecol. 2002;109:34–43. doi: 10.1111/j.1471-0528.2002.00432.x.
    1. Lobos O., Padila C. Phenotypic characterisation and genomic DNA polymorphisms of Escherichia coli strains isolated as the sole microorganisms from vaginal infections. Microbiology. 2009;3:825–830. doi: 10.1099/mic.0.021733-0.
    1. Sobel J.D., Reichman O., Misra D., Yoo W. Prognosis and treatment of desquamative inflammatory vaginitis. Obstet. Gynecol. 2011;117:850–855. doi: 10.1097/AOG.0b013e3182117c9e.
    1. Sobel J.D. Vulvovaginal candidosis. Lancet. 2007;369:1961–1971. doi: 10.1016/S0140-6736(07)60917-9.
    1. Centers for Disease Control and Prevention-2015 Sexually Transmitted Diseases Treatment Guidelines Diseases Characterized by Vaginal Discharge-CDC Bacterial Vaginosis. [(accessed on 14 February 2018)]; Available online: .
    1. Borges S., Silva J., Teixeira P. The role of lactobacilli and probiotics in maintaining vaginal health. Arch. Gynecol. Obstet. 2014;289:479–489. doi: 10.1007/s00404-013-3064-9.
    1. Beigi R.H., Austin M.N., Meyn L.A., Krohn M.A., Hillier S.L. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am. J. Obstet. Gynecol. 2004;191:1124–1129. doi: 10.1016/j.ajog.2004.05.033.
    1. Ferris M.J., Masztal A., Aldridge K.E., Fortenberry J.D., Fidel P.L., Jr., Martin D.H. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect. Dis. 2004;4:5. doi: 10.1186/1471-2334-4-5.
    1. Bradshaw C.S., Tabrizi S.N., Fairley C.K., Morton A.N., Rudland E., Garland S.M. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J. Infect. Dis. 2006;194:828–836. doi: 10.1086/506621.
    1. Bradshaw C.S., Morton A.N., Hocking J., Garland S.M., Morris M.B., Moss L.M., Horvath L.B., Kuzevska I., Fairley C.K. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J. Infect. Dis. 2006;193:1478–1486. doi: 10.1086/503780.
    1. Cribby S., Taylor M., Reid G. Vaginal microbiota and the use of probiotics. Interdiscip. Perspect. Infect. Dis. 2008;2008:256490. doi: 10.1155/2008/256490.
    1. Homayouni A., Bastani P., Ziyadi S., Mohammad-Alizadeh-Charandabi S., Ghalibaf M., Mortazavian A.M., Mehrabany E.V. Effects of probiotics on the recurrence of bacterial vaginosis: A review. Low Genit. Tract Dis. 2014;18:79–86. doi: 10.1097/LGT.0b013e31829156ec.
    1. Nyirjesy P., Robinson J., Mathew L., Lev-Sagie A., Reyes I., Culhane J.F. Alternative therapies in women with chronic vaginitis. Obstet. Gynecol. 2011;117:856–861. doi: 10.1097/AOG.0b013e31820b07d5.
    1. Health and Nutrition Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Food and Agriculture Organization of the United Nations and World Health Organization; Córdoba, Argentina: 2001. [(accessed on 1 May 2006)]. Available online: .
    1. Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., Scott K., Stanton C., Swanson K.S., Cani P.D., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491–502. doi: 10.1038/nrgastro.2017.75.
    1. Bertuccini L., Russo R., Iosi F., Superti F. Lactobacilli and lactoferrin: Biotherapeutic effects for vaginal health. J. Funct. Foods. 2018;45:86–94. doi: 10.1016/j.jff.2018.03.033.
    1. González-Chávez S.A., Arévalo-Gallegos S., Rascón-Cruz Q. Lactoferrin: Structure, function and applications. Int. J. Antimicrob. Agents. 2009;33:301.e1–301.e8. doi: 10.1016/j.ijantimicag.2008.07.020.
    1. Kim W.S., Ohashi M., Tanaka T., Kumura H., Kim G.Y., Kwon I.K., Goh J.S., Shimazaki K. Growth-promoting effects of lactoferrin on L. acidophilus and Bifidobacterium spp. Biometals. 2004;17:279–283. doi: 10.1023/B:BIOM.0000027705.57430.f1.
    1. Rahman M.M., Kim W.S., Ito T., Kumura H., Shimazaki K. Growth promotion and cell binding ability of bovine lactoferrin to Bifidobacterium longum. Anaerobe. 2009;15:133–137. doi: 10.1016/j.anaerobe.2009.01.003.
    1. Orsi N. The antimicrobial activity of lactoferrin: Current status and perspectives. Biometals. 2004;17:189–196. doi: 10.1023/B:BIOM.0000027691.86757.e2.
    1. Baker H.M., Baker E.N. Lactoferrin and iron: Structural and dynamic aspects of binding and release. Biometals. 2004;17:209–216. doi: 10.1023/B:BIOM.0000027694.40260.70.
    1. Superti F., Berlutti F., Paesano R., Valenti P. Structure and activity of lactoferrin-a multi functional protective agent for human health. In: Fuchs H., editor. Iron Metabolism and Disease. Volume 8. Publisher Research Signpost; Trivandrum, India: 2008. pp. 1–32.
    1. Liu B., Newburg D.S. Human Milk Glycoproteins Protect Infants Against Human Pathogens. Breastfeed. Med. 2013;8:354–362. doi: 10.1089/bfm.2013.0016.
    1. Lupetti A., Paulusma-Annema A., Welling M.M., Dogterom-Ballering H., Brouwer C.P., Senesi S., Van Dissel J.T., Nibbering P.H. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob. Agents Chemother. 2003;47:262–267. doi: 10.1128/AAC.47.1.262-267.2003.
    1. Andrés M.T., Viejo-Díaz M., Fierro J.F. Human lactoferrin induces apoptosis-like cell death in Candida albicans: Critical role of K+-channel-mediated K+ efflux. Antimicrob. Agents Chemother. 2008;52:4081–4088. doi: 10.1128/AAC.01597-07.
    1. Sessa R., Di Pietro M., Filardo S., Bressan A., Mastromarino P., Biasucci A.V., Rosa L., Cutone A., Berlutti F., Paesano R., et al. Lactobacilli-lactoferrin interplay in Chlamydia trachomatis infection. Pathog. Dis. 2017;75 doi: 10.1093/femspd/ftx054.
    1. Naidu A.S., Miedzobrodzki J., Musser J.M., Rosdahl V.T., Hedström S.A., Forsgren A. Human lactoferrin binding in clinical isolates of Staphylococcus aureus. J. Med. Microbiol. 1991;34:323–328. doi: 10.1099/00222615-34-6-323.
    1. Otsuki K., Yakuwa K., Sawada M., Hasegawa A., Sasaki Y., Mitsukawa K., Chiba H., Nagatsuka M., Saito H., Okai T. Recombinant human lactoferrin has preventive effects on lipopolysaccharide-induced preterm delivery and production of inflammatory cytokines in mice. J. Perinat. Med. 2005;33:320–323. doi: 10.1515/JPM.2005.057.
    1. Wakabayashi H., Abe S., Okutomi T., Tansho S., Kawase K., Yamaguchi H. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol. 1996;40:821–825. doi: 10.1111/j.1348-0421.1996.tb01147.x.
    1. Fernandes K.E., Carter D.A. The Antifungal Activity of Lactoferrin and Its Derived Peptides: Mechanisms of Action and Synergy with Drugs against Fungal Pathogens. Front. Microbiol. 2017;8:2. doi: 10.3389/fmicb.2017.00002.
    1. Yakuwa K., Otsuki K., Nakayama K., Hasegawa A., Sawada M., Mitsukawa K., Chiba H., Nagatsuka M., Okai T. Recombinant human lactoferrin has a potential to suppresses uterine cervical ripening in preterm delivery in animal model. Arch. Gynecol. Obstet. 2007;275:331–334. doi: 10.1007/s00404-006-0261-9.
    1. Falagas M., Betsi G.I., Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin. Microbiol. Infect. 2007;13:657–664. doi: 10.1111/j.1469-0691.2007.01688.x.
    1. Abad C.L., Safdar N. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections—A systematic review. J. Chemother. 2009;21:243–352. doi: 10.1179/joc.2009.21.3.243.
    1. Ventura M., O’Flaherty S., Claesson M.J., Turroni F., Klaenhammer T.R., van Sinderen D., O’Toole P.W. Genome-scale analyses of health-promoting bacteria: Probiogenomics. Nat. Rev. Microbiol. 2009;7:61–71. doi: 10.1038/nrmicro2047.
    1. Boris S., Suárez J.E., Vázquez F., Barbés C. Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction with uropathogens. Infect. Immun. 1998;66:1985–1989. doi: 10.1128/IAI.66.5.1985-1989.1998.
    1. Pino A., Bartolo E., Caggia C., Cianci A., Randazzo C.L. Detection of vaginal lactobacilli as probiotic candidates. Sci. Rep. 2019;9:3355. doi: 10.1038/s41598-019-40304-3.
    1. Allonsius C.N., van den Broek M.F.L., De Boeck I., Kiekens S., Oerlemans E.F.M., Kiekens F., Foubert K., Vandenheuvel D., Cos P., Delputte P., et al. Interplay between Lactobacillus rhamnosus GG and Candida and the involvement of exopolysaccharides. Microb. Biotechnol. 2017;10:1753–1763. doi: 10.1111/1751-7915.12799.
    1. Coudeyras S., Jugie G., Vermerie M., Forestier C. Adhesion of human probiotic Lactobacillus rhamnosus to cervical and vaginal cells and interaction with vaginosis-associated pathogens. Infect. Dis. Obstet. Gynecol. 2008;2008:549640. doi: 10.1155/2008/549640.
    1. Calonghi N., Parolin C., Sartor G., Verardi L., Giordani B., Frisco G., Marangoni A., Vitali B. Interaction of vaginal Lactobacillus strains with HeLa cells plasma membrane. Benef. Microbes. 2017;8:625–633. doi: 10.3920/BM2016.0212.
    1. Atassi F., Brassart D., Grob P., Graf F., Servin A.L. Lactobacillus strains isolated from the vaginal microbiota of healthy women inhibit Prevotella bivia and Gardnerella vaginalis in coculture and cell culture. FEMS Immunol. Med. Microbiol. 2006;48:424–432. doi: 10.1111/j.1574-695X.2006.00162.x.
    1. Parolin C., Marangoni A., Laghi L., Foschi C., Ñahui Palomino R.A., Calonghi N., Cevenini R., Vitali B. Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity. PLoS ONE. 2015;10:e0131220. doi: 10.1371/journal.pone.0131220.
    1. Castro J., Henriques A., Machado A., Henriques M., Jefferson K.K., Cerca N. Reciprocal interference between Lactobacillus spp. and Gardnerella vaginalis on initial adherence to epithelial cells. Int. J. Med. Sci. 2013;10:1193–1198. doi: 10.7150/ijms.6304.
    1. Wagner R.D., Johnson S.J. Probiotic Lactobacillus and estrogen effects on vaginal epithelial gene expression responses to Candida albicans. J. Biomed. Sci. 2012;19:58. doi: 10.1186/1423-0127-19-58.
    1. Bertuccini L., Russo R., Iosi F., Superti F. Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens. Int. J. Immunopathol. Pharmacol. 2017;30:163–167. doi: 10.1177/0394632017697987.
    1. Jang S.E., Jeong J.J., Choi S.Y., Kim H., Han M.J., Kim D.H. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 Attenuate Gardnerella vaginalis-Infected Bacterial Vaginosis in Mice. Nutrients. 2017;9:531. doi: 10.3390/nu9060531.
    1. Gill H.S., Rutherfurd K.J., Prasad J., Gopal P.K. Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) Br. J. Nutr. 2000;83:167–176. doi: 10.1017/S0007114500000210.
    1. De Gregorio P.R., Silva J.A., Marchesi A., Nader-Macías M.E.F. Anti-Candida activity of beneficial vaginal lactobacilli in in vitro assays and in a murine experimental model. FEMS Yeast Res. 2019;19:foz008. doi: 10.1093/femsyr/foz008.
    1. Siroli L., Patrignani F., Serrazanetti D.I., Parolin C., Ñahui Palomino R.A., Vitali B., Lanciotti R. Determination of Antibacterial and Technological Properties of Vaginal Lactobacilli for Their Potential Application in Dairy Products. Front. Microbiol. 2017;8:166. doi: 10.3389/fmicb.2017.00166.
    1. Shu Q., Gill H.S. Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) against Escherichia coli O157:H7 infection in mice. FEMS Immunol. Med. Microbiol. 2002;34:59–64. doi: 10.1016/S0928-8244(02)00340-1.
    1. Chen P.W., Jheng T.T., Shyu C.L., Mao F.C. Antimicrobial potential for the combination of bovine lactoferrin or its hydrolysate with lactoferrin-resistant probiotics against foodborne pathogens. J. Dairy Sci. 2013;96:1438–1446. doi: 10.3168/jds.2012-6112.
    1. Chen P.W., Jheng T.T., Shyu C.L., Mao F.C. Synergistic antibacterial efficacies of the combination of bovine lactoferrin or its hydrolysate with probiotic secretion in curbing the growth of meticillin-resistant Staphylococcus aureus. J. Med. Microbiol. 2013;62:1845–1851. doi: 10.1099/jmm.0.052639-0.
    1. Chen P.W., Ku Y.W., Chu F.Y. Influence of bovine lactoferrin on the growth of selected probiotic bacteria under aerobic conditions. Biometals. 2014;27:905–914. doi: 10.1007/s10534-014-9758-z.
    1. Tian H., Maddox I.S., Ferguson L.R., Shu Q. Influence of bovine lactoferrin on selected probiotic bacteria and intestinal pathogens. Biometals. 2010;23:593–596. doi: 10.1007/s10534-010-9318-0.
    1. Chen P.W., Liu Z.S., Kuo T.C., Hsieh M.C., Li Z.W. Prebiotic effects of bovine lactoferrin on specific probiotic bacteria. Biometals. 2017;30:237–248. doi: 10.1007/s10534-017-9999-8.
    1. Sherman M.P., Bennett S.H., Hwang F.F., Yu C. Neonatal small bowel epithelia: Enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG. Biometals. 2004;17:285–289. doi: 10.1023/B:BIOM.0000027706.51112.62.
    1. Liao H., Liu S., Wang H., Su H., Liu Z. Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis. BMC Microbiol. 2019;19:7. doi: 10.1186/s12866-018-1370-x.
    1. Otsuki K., Tokunaka M., Oba T., Nakamura M., Shirato N., Okai T. Administration of oral and vaginal prebiotic lactoferrin for a woman with a refractory vaginitis recurring preterm delivery: Appearance of lactobacillus in vaginal flora followed by term delivery. J. Obstet. Gynaecol. Res. 2014;40:583–585. doi: 10.1111/jog.12171.
    1. Otsuki K., Imai N. Effects of lactoferrin in 6 patients with refractory bacterial vaginosis. Biochem. Cell Biol. 2017;95:31–33. doi: 10.1139/bcb-2016-0051.
    1. Pino A., Giunta G., Randazzo C.L., Caruso S., Caggia C., Cianci A. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: An open prospective randomized trial. Microb. Ecol. Health Dis. 2017;28:1357417. doi: 10.1080/16512235.2017.1357417.
    1. Costantino D., Guaraldi C. Preliminary evaluation of a vaginal cream containing lactoferrin in the treatment of vulvovaginal candidosis. Minerva Ginecol. 2008;60:121–125.
    1. Marelli G., Papaleo E., Ferrari A. Lactobacilli for prevention of urogenital infections: A review. Eur. Rev. Med. Pharmacol. Sci. 2004;8:87–95.
    1. Mastromarino P., Macchia S., Meggiorini L., Trinchieri V., Mosca L., Perluigi M., Midulla C. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin. Microbiol. Infect. 2009;15:67–74. doi: 10.1111/j.1469-0691.2008.02112.x.
    1. Barrons R., Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: A review. Clin. Ther. 2008;30:453–468. doi: 10.1016/j.clinthera.2008.03.013.
    1. Dover S.E., Aroutcheva A.A., Faro S., Chikindas M.L. Natural antimicrobials and their role in vaginal health: A short review. Int. J. Probiotics Prebiotics. 2008;3:219–230.
    1. Reid G., Bruce A.W., Fraser N., Heinemann C., Owen J., Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol. Med. Microbiol. 2001;30:49–52. doi: 10.1111/j.1574-695X.2001.tb01549.x.
    1. Del Popolo G., Nelli F. Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment. Arch. Ital. Urol. Androl. 2018;90:101–103. doi: 10.4081/aiua.2018.2.101.
    1. Cadieux P.A., Burton J., Devillard E., Reid G. Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. J. Physiol Pharmacol. 2009;60:13–18.
    1. Van de Wijgert J.H.H.M., Verwijs M.C. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: A systematic review and recommendations for future trial designs. BJOG. 2019 doi: 10.1111/1471-0528.15870.
    1. Xie H.Y., Feng D., Wei D.M., Mei L., Chen H., Wang X., Fang F. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst. Rev. 2017;11:CD010496. doi: 10.1002/14651858.CD010496.pub2.
    1. Shukla A., Sobel J.D. Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. Curr. Infect. Dis. Rep. 2019;21:44. doi: 10.1007/s11908-019-0700-y.
    1. Senok A.C., Verstraelen H., Temmerman M., Botta G.A. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev. 2009;4:CD006289. doi: 10.1002/14651858.CD006289.pub2.
    1. Gille C., Böer B., Marschal M., Urschitz M.S., Heinecke V., Hund V., Speidel S., Tarnow I., Mylonas I., Franz A., et al. Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial. Am. J. Obstet. Gynecol. 2016;215:608.e1–608.e7. doi: 10.1016/j.ajog.2016.06.021.
    1. De Alberti D., Russo R., Terruzzi F., Nobile V., Ouwehand A.C. Lactobacilli vaginal colonisation after oral consumption of Respecta (®) complex: A randomised controlled pilot study. Arch. Gynecol. Obstet. 2015;292:861–867. doi: 10.1007/s00404-015-3711-4.
    1. Russo R., Edu A., De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch. Gynecol Obstet. 2018;298:139–145. doi: 10.1007/s00404-018-4771-z.
    1. Russo R., Karadja E., De Seta F. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: A double blind, placebo controlled, randomised clinical trial. Benef. Microbes. 2019;10:19–26. doi: 10.3920/BM2018.0075.
    1. Russo R., Superti F., Karadja E., De Seta F. Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019;62:328–335. doi: 10.1111/myc.12883.
    1. De Simone C. The unregulated probiotic market. Clin. Gastroenterol. Hepatol. 2019;17:809–817. doi: 10.1016/j.cgh.2018.01.018.
    1. Kolaček S., Hojsak I., Berni Canani R., Guarino A., Indrio F., Orel R., Pot B., Shamir R., Szajewska H., Vandenplas Y., et al. Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J. Pediatr. Gastroenterol. Nutr. 2017;65:117–124. doi: 10.1097/MPG.0000000000001603.
    1. Prestinaci F., Pezzotti P., Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog. Glob. Health. 2015;109:309–318. doi: 10.1179/2047773215Y.0000000030.
    1. Marrazzo J.M., Cook R.L., Wiesenfeld H.C., Murray P.J., Busse B., Krohn M., Hillier S.L. Women’s satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosis. J. Womens Health (Larchmt) 2006;15:1053–1060. doi: 10.1089/jwh.2006.15.1053.
    1. Hemmerling A., Harrison W., Schroeder A., Park J., Korn A., Shiboski S., Foster-Rosales A., Cohen C.R. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex. Transm. Dis. 2010;37:745–750. doi: 10.1097/OLQ.0b013e3181e50026.
    1. Czaja C.A., Stapleton A.E., Yarova-Yarovaya Y., Stamm W.E. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect. Dis. Obstet. Gynecol. 2007;2007:35387. doi: 10.1155/2007/35387.
    1. Stapleton A.E., Au-Yeung M., Hooton T.M., Fredricks D.N., Roberts P.L., Czaja C.A., Yarova-Yarovaya Y., Fiedler T., Cox M., Stamm W.E. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. 2011;52:1212–1217. doi: 10.1093/cid/cir183.
    1. Grin P.M., Kowalewska P.M., Alhazzan W., Fox-Robichaud A.E. Lactobacillus for preventing recurrent urinary tract infections in women: Meta-analysis. Can. J. Urol. 2013;20:6607–6614.
    1. Ho M., Chang Y.Y., Chang W.C., Lin H.C., Wang M.H., Lin W.C., Chiu T.H. Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: A randomized controlled trial. Taiwan J. Obstet. Gynecol. 2016;55:515–518. doi: 10.1016/j.tjog.2016.06.003.
    1. Olsen P., Williamson M., Traynor V., Georgiou C. The impact of oral probiotics on vaginal Group B Streptococcal colonisation rates in pregnant women: A pilot randomised control study. Women Birth. 2018;31:31–37. doi: 10.1016/j.wombi.2017.06.012.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren